Skip to main content

Table 2 HBV serostatus and clinical course of 17 cases with detectable hepatitis B virus (HBV) DNA during biologic therapy

From: Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study

ID

Disease

Baseline

At HBV DNA detection

Clinical course after HBV DNA detected

HBV serostatus

ALT (IU/mL)

DMARDs

Months since enrolled

HBV serostatus

ALT (IU/mL)

DMARDs

Medication change on detecting HBV DNA

Preemptive antiviral therapy

Serial HBV DNA and outcome

sAg (+/−)

sAb (mIU/mL)

DNA (IU/mL)

sAg (+/−)

sAb (mIU/mL)

DNA (IU/mL)

1

RA

–

< 10

< 10

18

Pd, RTX

9

–

< 10

31

27

Pd, RTX

No

No

Fluctuating without reactivation

2

RA

–

< 10

< 10

20

Pd, MTX, ETA

30

–

< 10

14

27

MTX, ETA

No

No

Spontaneously became undetectable without reactivation

3

AS

–

NA

< 10

13

ADA

27

+

< 10

99

9

ADA

No

No

Fluctuating without reactivation

4

RA

–

< 10

< 10

20

Pd, MTX

27

–

< 10

17

18

Pd, MTX, RTX

RTX → TCZ

No

Spontaneously became undetectable without reactivation

5

RA

–

< 10

< 10

17

Pd, MTX, GOL

5

–

< 10

13

22

Pd, MTX, RTX

No

No

Fluctuating without reactivation

6

RA

–

< 10

< 10

30

Pd, ETA

20

–

< 10

464

17

Pd, ETA

No

No

Spontaneously became undetectable without reactivation

7

RA

–

16.7

< 10

18

Pd, MTX

36

–

< 10

14

17

Pd, MTX, RTX

No

No

Fluctuating without reactivation

8

RA

–

23.8

< 10

16

MTX, ETA

28

–

12.8

30

14

MTX, ETA

No

No

Spontaneously became undetectable without reactivation

9

RA

–

152

< 10

17

Pd, MTX, RTX

30

–

68

22

13

Pd, MTX, RTX

No

No

Spontaneously became undetectable without reactivation

10

RA

NA

110

< 10

34

Pd, RTX

7

NA

83

435

54

Pd, RTX

Hold RTX

No

No reactivation

11

RA

–

26

< 10

16

MTX, ETA

48

–

85

11

20

Pd, MTX, GOL

No

No

Spontaneously became undetectable without reactivation

12

RA

–

44

< 10

27

Pd, MTX, ABA

17

–

38

11

45

Pd, MTX, RTX

No

No

Fluctuating without reactivation

13

RA

–

NA

< 10

16

Pd, MTX

27

–

93

66

20

Pd, MTX, ADA

No

No

No reactivation

14

RA

–

47.2

< 10

26

Pd, MTX, ADA

24

–

26

35

36

Pd, MTX, RTX

RTX → TCZ

No

Spontaneously became undetectable without reactivation

15

RA

–

4

< 10

39

Pd, MTX

39

–

14

11

23

MTX, ETA

No

No

Fluctuating without reactivation

16

RA

NA

< 10

< 10

36

Pd, LEF, RTX

15

–

< 10

12

36

Pd, LEF

RTX

No

No

Fluctuated to become undetectable then reactivated 5 months after initiating ABA

17

RA

NA

93

< 10

39

ADA

18

–

63

90

33

RTX

No

No

Reactivation 7 months after detecting HBV DNA

  1. Definitions: HBsAb < 10 mIU/mL: negative; HBV DNA < 10 IU/mL: undetectable; ALT < 40 IU/L: within normal limit
  2. ABA abatacept, ADA adalimumab, ALT alanine transaminase, AS ankylosing spondylitis, DMARD disease-modifying anti-rheumatic drug, ETA etanercept, GOL golimumab, ID case code number, LEF leflunomide, MTX methotrexate, NA not available, Pd prednisolone, RA rheumatoid arthritis, RTX rituximab, sAb surface antibody, sAg surface antigen, TCZ tocilizumab
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us